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ABSTRACT 
 
Polygenic risk scores (PRSs) have been used to combine the effects of variants with small effects 
identified by genome-wide association studies. We explore the potential for using pathway 
specific PRSs as predictors of early changes in Alzheimer’s disease (AD)-related biomarkers. 
Participants were from the Wisconsin Registry for Alzheimer’s Prevention, a longitudinal study 
of initially asymptomatic adults enriched for a parental history of AD. Using the genes 
associated with AD in the International Genomics of Alzheimer’s Project’s meta-analysis, we 
identified clusters of genes that grouped into pathways involved in Aβ deposition: Aβ clearance 
and cholesterol metabolism. Weighted pathway specific and overall PRSs were developed and 
compared to APOE alone. Mixed models were used to assess whether each PRS was associated 
with cognition in 1,200 individuals, cerebral Aβ deposition measured using amyloid ligand 
(Pittsburgh compound B) positron emission imaging (PET) in 168 individuals, and cerebrospinal 
fluid (CSF) Aβ levels in 111 individuals. We found that the Cholesterol Metabolism PRS tended 
to be either a similar or stronger predictor than APOE, while both the Cholesterol and Aβ 
Clearance PRSs were stronger predictors than the Overall PRS. Thus, for investigations of 
disease-related traits, limiting a PRS to variants known to contribute to a biological pathway of 
the particular trait may be a more informative approach than including variants known to 
contribute to the disease more broadly. In the future, pathway specific PRSs could be used to 
prioritize screening for Aβ accumulation. 
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INTRODUCTION 
Alzheimer’s disease (AD) is clinically characterized by a decline in cognitive function. 
However, β-amyloid (Aβ) deposits as plaques and hyperphosphorylation and aggregation of tau 
into tangles are believed to have accumulated in the brain of an AD patient long before cognitive 
decline is evident[1]. This accumulation causes blocked neural signaling and nutrient transport, 
respectively, and is thought to lead to the characteristic neurodegeneration of AD. It has been 
hypothesized that an imbalance between Aβ production and Aβ clearance leads to Aβ 
accumulation (REF). Aβ clearance rates have been shown to be reduced in late onset AD 
(LOAD) patients while  Aβ production rates appear to be normal[2]. Changes in cholesterol 
metabolism is another characteristic of AD and may be closely linked to Aβ production and Aβ 
clearance[3]. Studying these risk factors could help explain the underlying genetic mechanisms 
that contribute to the onset of AD.  
In a meta-analysis of genome-wide association studies (GWAS) that included over 
74,000 individuals with and without LOAD, 11 novel susceptibility single nucleotide 
polymorphisms (SNPs) were identified, as well as 8 that had previously been found to be 
associated with LOAD[4]. While this study confirmed that many genetic factors contribute to the 
risk of LOAD, these variants each have fairly small effect sizes (Supplementary Table 1). 
Polygenic risk scores (PRSs) utilize allele-counting methods to combine the effects of many 
individual SNPs and have been found to produce good predictors[5, 6].  While an overall PRS 
that combines the effects of all LOAD associated SNPs may be powerful for predicting cognitive 
function and decline due to underlying LOAD pathology, a pathway specific PRS[7] may be 
more powerful for LOAD biomarkers, such as Aβ deposition. 
Using a longitudinal sample of cognitively healthy adults enriched for a parental history 
of LOAD from the Wisconsin Registry for Alzheimer’s Prevention (WRAP), we explore the 
potential for using pathway specific PRSs as predictors of early changes in AD-related 
biomarkers. In particular, we created weighted PRSs for Aβ Clearance and Cholesterol 
Metabolism, in addition to an Overall PRS, using the single most significant variant from each 
gene identified to be associated with LOAD in the International Genomics of Alzheimer’s 
Project’s (IGAP) meta-analysis. These PRSs were assessed against cerebrospinal fluid (CSF) 
levels of Aβ42 (reflecting Aβ deposition in the brain) and tau protein (reflecting 
neurodegeneration) for relevant PRSs, [C-11]Pittsburgh compound B (PiB) positron emission 
tomography (PET), and cognition. This unique study design could have the potential to identify 
individuals at increased genetic risk for AD pathology before the onset of clinical symptoms.  
This could be particularly useful as therapies to target particular pathways become available.  
 
MATERIALS AND METHODS 
Participants 
Study participants were from WRAP, a longitudinal study of initially asymptomatic 
middle-aged adults enriched for a parental history of LOAD. A positive parental history was 
defined as having one or both parents with either autopsy-confirmed or probable AD as defined 
by NINCDS-ADRDA research criteria[8]. Baseline recruitment began in 2001 with initial follow 
up after 4 years and subsequent ongoing follow up every 2 years. Further details of the study 
design and methods used have been previously described[9-11].  
The present analyses were limited to non-Hispanic Caucasian participants due to sample 
size limitations of other racial groups. Participants were excluded if they reported having 
diseases or comorbidities that might be expected to influence cognitive test performance (e.g., 
multiple sclerosis, Parkinson’s disease, stroke, epilepsy/seizures, or meningitis) or developed AD 
on or before the second visit. 
This study was conducted with the approval of the University of Wisconsin Institutional 
Review Board and all subjects provided signed informed consent before participation. 
 
DNA Collection, Genotyping, and Quality Control 
DNA was extracted from whole blood samples using the PUREGENE® DNA Isolation 
Kit (Gentra Systems, Inc., Minneapolis, MN). DNA concentrations were quantified using UV 
spectrophotometry (DU® 530 Spectrophotometer, Beckman Coulter, Fullerton, CA). 
A total of 37 SNPs in 1,448 individuals were genotyped by LGC Genomics (Beverly, 
MA) using competitive allele-specific PCR based KASPTM genotyping assays. Duplicate quality 
control (QC) samples from 102 individuals were placed randomly throughout each of the 96-well 
plates. The genotype concordance rate was 99.89%. All discordant genotypes were set to 
missing. To assess the potential for sample mislabeling, we checked concordance against a 
previous round of genotyping that included three overlapping variants (rs7412 and rs429358 in 
apolipoprotein E (APOE), and rs6656401 in CR1) in 1,152 individuals. Six genotypes were 
discordant in six different individuals, who were removed from further analyses. 
Further QC was conducted using PLINK v1.07[12]. We removed 27 individuals due to 
high missingness (>10%), 0 SNPs due to low call rates (<95%), and 4 SNPs due to being 
monomorphic in our sample (2 SNPs from an African-American GWAS meta-analysis[13]: 
rs145848414 (an intergenic SNP on chromosome 5) and rs6973770 in EPHA1-AS1, as well as 
rs4819 in PLD3, and rs63750847 in APP). Hardy-Weinberg equilibrium (HWE) was assessed 
among a subset of 1,120 unrelated individuals using a Bonferroni adjusted p-value threshold of 
.05/33=.0015. One SNP failed HWE (p=.00104) but was kept due to the marginal difference 
from the p-value threshold to allow for comparison to existing literature (rs28834970 in PTK2B). 
This left a total of 1,415 individuals and 33 SNPs after the completion of all QC procedures. The 
present analyses used 21 of these SNPs: the 19 IGAP SNPs (Supplementary Table 1) and the 2 
APOE SNPs (Table 1). 
 
Polygenic Risk Scores 
Pathway specific PRSs were determined according to existing literature and included Aβ 
Clearance (PICALM, CLU, CR1, and APOE)[14, 15] and Cholesterol Metabolism (ABCA7, 
CLU, and APOE)[3, 16]. An Overall PRS (including all of the IGAP genes, as listed in 
Supplementary Table 1, plus APOE) and an APOE alone risk score were also created for 
comparison. PRSs were calculated for each participant using the following equation:, where i 
represents the individual, whose score is calculated by summing over all SNPs, n, in the pathway 
ranging from l to k; OR is the odds ratio of SNP n; and C is the individual’s count of risk alleles 
for SNP n. If the minor allele was protective, the inverse of the OR was used instead as follows: . 
With the exception of APOE, SNP ORs used in this analysis were taken from the IGAP meta-
analysis and are indicated in Table 1. Risk due to APOE was not calculated additively, but 
instead according to the OR of the 2/3/4 genotype formed by SNPs rs429358 and rs7412, as 
indicated in AlzGene[17]. Since APOE is known to have a large effect size, PRSs were also 
calculated excluding APOE to determine the effect of the PRS beyond that of APOE alone.  
 
Neuropsychometric Assessments 
The WRAP cognitive test battery consists of standardized widely used clinical 
neuropsychological tests, which were selected to provide a comprehensive estimate of cognitive 
abilities with an emphasis on abilities most likely to be affected in early-stage AD. Factor 
analysis was conducted to reduce the number of outcome measures to a smaller number of 
reliable cognitive factors and obtain weights used to combine the measures within each 
factor[18]. The following 6 cognitive factor scores were used in the present analysis: Immediate 
Memory, Verbal Learning and Memory, Speed and Flexibility, Visual Learning and Memory, 
Story Recall, and Working Memory. Tests comprising each of these factors are described 
elsewhere[19]. The resulting weighted factor scores were then standardized (~N [0,1]) into z-
scores, using means and standard deviations obtained from the whole baseline sample.  
 
PiB PET Imaging 
[C-11]Pittsburgh compound B (PiB) positron emission tomography (PET) radiochemical 
synthesis, acquisition parameters and generation of distribution volume ratio (DVR) maps were 
detailed previously[20]. Briefly, after a 70 minute dynamic [C-11]PiB PET acquisition, PET data 
were reconstructed using a filtered back-projection algorithm (DIFT) and were corrected for 
random events, attenuation of annihilation radiation, deadtime, scanner normalization, and 
scatter radiation and were realigned and coregistered in SPM12. The data were then transformed 
into voxel-wise DVR maps of [C-11]PiB binding using the time activity curve in the gray matter 
of the cerebellum as the reference region. 
To reduce the number of statistical tests, a summary measure of amyloid burden was 
calculated by averaging the means of amyloid binding within 8 bilateral regions of interest, as 
previously described[21].  
 
CSF quantification  
CSF was collected via lumbar puncture (LP) in the morning after a 12-hour fast using a 
Sprotte 25- or 24-gauge spinal needle at L3/4 or L4/5 using gentle extraction into polypropylene 
syringes. CSF (22 mL) was then combined, gently mixed, and centrifuged at 2000g for 10 
minutes. Supernatants were frozen in 0.5 mL aliquots in polypropylene tubes and stored at 
−80°C. 
  CSF Aβ42, total tau (T-tau), and phosphorylated tau (p-tau) were quantified with 
sandwich ELISAs (INNOTEST β-amyloid1-42, hTAU-Ag, and Phospho-Tau[181P], 
respectively; Fujirebio Europe, Ghent, Belgium). For the Aβ42/Aβ40 ratio, CSF levels of Aβ42 and 
Aβ40 (a less amyloidogenic Aβ fragment as compared to Aβ42) were quantified by 
electrochemiluminescence (ECL) using an Aβ triplex assay (MSD Human Aβ peptide Ultra-
Sensitive Kit, Meso Scale Discovery, Gaithersburg, MD). All measurements were performed in 
one round of analyses using one batch of reagents by board-certified laboratory technicians who 
were blind to the clinical characteristics of participants. Intra-assay coefficients of variation were 
below 10%. 
 
Statistical Analyses 
Each individual SNP and PRS was included in a linear mixed effects regression model to 
test for association with the 6 cognitive factor outcomes and Aβ deposition, adjusting for age and 
gender. Since genetic effects often vary by age, models were also stratified by the median age of 
the given subset of participants (i.e., full sample, CSF, and PiB). For individuals with multiple 
observations, age at each observation was considered instead of categorizing an individual by 
their age at a particular time point. Random effects for the intercept, participant, and family were 
included to account for dependency within and between participant’s observations and family 
members. The variance structure used for each outcome was determined using unconditional 
growth models that included a fixed effect of time. Variance structures tested included 
unstructured, compound symmetry, and variance components, and that with the lowest Akaike 
Information Criterion (AIC) was used for the corresponding outcome. Unconditional growth 
models were similarly used to compare the inclusion of a random effect for time for each 
outcome. In all models, age was used as the measure of time, as time between visits could vary 
slightly within and between individuals.  
 
RESULTS 
Participants 
A total of 1,200 participants met study criteria and had cognitive data available for up to 
five visits. A subset of 111 and 168 of these participants had CSF and PiB data, respectively, for 
up to two visits. At baseline, the full set of participants were 53.6 years of age on average, fairly 
well educated, predominantly female, and most had a parental history of AD. As expected, this 
sample had a higher frequency of the APOE ε4 allele and lower frequency of the ε2 allele than 
the general population. These characteristics were fairly consistent within the two subsets of 
participants, although the mean age was about 7 years older in both of them when compared to 
the full set of participants, since these studies were ancillary to and began later than the main 
WRAP study. Participant characteristics are described further in Table 1. 
The distribution of each PRS and the APOE risk score are described for the full sample in 
Supplementary Table 2. As expected, the mean PRSs were lower when APOE was excluded. 
  
Cognitive Outcomes 
There were fewer associations between single SNPs and cognitive outcomes than 
expected by chance and of the three significant effects, two were not in the expected direction 
based on the IGAP results (Supplementary Table 3). Effects of the associations between the 
PRSs and cognitive outcomes were almost always in the direction expected, suggesting that a 
higher Aβ Clearance, Cholesterol, and Overall PRS trend towards lower cognition (although 
most of these relationships were not statistically significant; Table 2). The two associations that 
met statistical significance were in the pathway specific PRSs with the outcome of Working 
Memory (p=.03, for both), which was also the only statistically significant outcome for APOE 
(p=.04). The model fit of the Aβ Clearance and Cholesterol PRSs compared to the model fit of 
APOE alone was better for each outcome, as measured by AIC, although the Overall PRS had 
the best model fit (results not shown). Upon removing APOE from the PRSs, the Aβ Clearance 
and Overall PRS associations became insignificant. However, a statistically significant 
relationship between higher Cholesterol PRS and lower Visual Learning and Memory scores 
appeared (p=.0498), which was not present while APOE was included in the PRSs. An 
association between the Overall PRS and Speed & Flexibility also appeared (p=.03), however, 
the effect was not in the expected direction (Table 2).  
 
Aβ Outcomes 
 The majority of associations between single SNPs and Aβ outcomes were insignificant, 
but 6 out of the 10 significant effects were in the expected direction based on IGAP results 
(Supplementary Table 4). All effects of the associations between the PRSs and Aβ outcomes 
were in the direction expected, although many of these relationships were not statistically 
significant (Table 3). A higher Aβ Clearance, Cholesterol, and Overall PRS were statistically 
associated with lower levels of Aβ42, a smaller Aβ42/Aβ40 ratio, and higher PiB, all indicators of 
Aβ deposition. A higher Cholesterol and Overall PRS were also statistically associated with 
higher P-tau/Aβ42 and T-Tau/Aβ42 ratios, indicating higher risk for AD. The pathway specific 
PRSs (Aβ Clearance and Cholesterol) were either equal or better predictors than APOE alone, 
while the significance of the Overall PRS relative to APOE alone was less consistent. APOE 
alone had a better model fit than the PRSs for P-tau/Aβ42, T-Tau/Aβ42, Aβ42/Aβ40, and PiB, while 
the Overall PRS had a better model fit for Aβ42, T-tau, and P-tau than APOE alone and the 
pathway specific PRSs (results not shown). Upon removing APOE from the PRSs, the strength 
of the associations was greatly attenuated, but the effects remained in the expected direction and 
the associations between the Cholesterol PRS and Aβ42/Aβ40, as well as T-tau/Aβ42 were still 
statistically significant (p=.02 and p=.048, respectively) (Table 3). 
 
Stratification by Age 
 The median age used to stratify analyses using cognitive outcomes was 58.00, while it 
was 62.56 for CSF outcomes and 62.48 for PiB, as the latter two sets of outcomes contained 
different subsets of participants from the complete sample.  
 As expected, APOE had the strongest effect in younger participants for most outcomes 
(Supplementary Table 5). This was most notable in Working Memory, Aβ42, T-tau/Aβ42, 
Aβ42/Aβ40, and PiB, where younger participants with a higher APOE risk score had significantly 
lower Working Memory scores, levels of Aβ42, and Aβ42/Aβ40, and higher levels of PiB and T-
tau/Aβ42 ratio, all risk factors for AD. The Aβ Clearance and Overall PRSs showed this stronger 
effect in younger participants, but upon removing APOE, differences between the age groups 
were not notable (results not shown). The Cholesterol PRS had a similar stronger effect in 
younger participants (Supplementary Table 6), however, upon removing APOE, the CSF and PiB 
outcomes showed the opposite effect, in which the PRS had a stronger effect in older individuals. 
This was particularly evident for the P-tau/Aβ42 (p=.03), T-tau/Aβ42 (p=.03), and Aβ42/Aβ40 
(p=.03) outcomes (Table 4). We further investigated these findings with an interaction term for 
age and the Cholesterol PRS excluding APOE and found that this interaction was significant for 
P-tau/Aβ42 (p=.03), marginally significant for T-tau/Aβ42 (p=.07), and insignificant for Aβ42/Aβ40 
(p=.14; results not shown). 
  
DISCUSSION 
In this investigation, we assessed the potential for pathway specific PRSs to predict AD-
related outcomes, including cognitive function and biomarkers of Aβ deposition (amyloid PET 
and CSF Aβ42), neurodegeneration (CSF T-tau) and tau pathology (CSF p-tau). Our findings 
suggest that the pathway specific PRS for Cholesterol Metabolism tended to perform either 
similarly or better than the APOE risk score alone, while both pathway specific PRSs (Aβ 
Clearance and Cholesterol) performed better than the Overall PRS. Thus, for investigations of 
disease-related traits or biomarkers, limiting a PRS to variants that are known to contribute to a 
biological pathway of the particular trait/biomarker may be a more informative approach than 
including variants known to contribute to the disease more broadly. Consistent with other 
studies, we also found that the PRSs were typically much better predictors of the outcomes than 
were single SNPs[22, 23].  
As expected, APOE was found to have a stronger effect in younger age for both cognitive 
outcomes and biomarkers of Aβ deposition. However, the opposite effect was seen for the 
Cholesterol PRS after removing APOE, such that it had a stronger effect in older age. This is a 
particularly interesting finding as it could suggest that the remaining variants in the Cholesterol 
PRS may interact with long-term accumulation of environmental risk factors to influence brain 
pathology later in life. More research is necessary to better understand the biological 
mechanisms driving this observation. 
The minimal statistically significant findings observed when assessing cognitive function 
is similar to the findings of another study that concluded that a PRS based on all IGAP genes, 
including APOE, was not associated with cognitive function after testing for associations with a 
battery of neuropsychological tests in older non-demented individuals[24]. Two other studies did 
find associations between a PRS using some IGAP genes and cognitive function, however, upon 
removing APOE from the PRS, associations were no longer significant[25, 26]. Even when 
APOE was included in our analyses, the Overall PRS was not statistically associated with any of 
the cognitive outcomes. However, our cognitive outcomes were factor scores combining several 
tests, while the other studies used individual test scores. Further, while 9 of the 11 genes 
included in the Verhaaren, et al. PRS and 8 of 10 genes in the Vivot, et al. PRS were IGAP 
genes, unlike our analysis, the variants used from each of these genes were not the most 
significant variants found in the IGAP meta-analysis. And lastly, because our sample had a 
younger mean age than these studies, it is possible that our sample may not have experienced 
sufficient cognitive decline to detect the effect of APOE on cognition. It is notable that our most 
consistent findings were in Working Memory, as we recently found that Working Memory has 
the highest heritability of the cognitive factor scores assessed here[19]. This could be because 
PRS analyses have been reported to have better power to detect associations when the traits have 
high heritability[27]. A much larger sample size may be needed to detect associations in 
cognitive traits with lower heritability. 
The observed association between the Overall PRS and CSF Aβ42 has been seen in other 
studies investigating the IGAP variants[22, 23]. Similar to our study, Sleegers, et al. found that 
upon removing APOE from the Overall PRS, this association was no longer significant. 
However, Martiskainen et al. found that this significance held upon removing APOE. Possible 
reasons for this difference could be due to the different SNPs included in the Martiskainen, et al. 
PRS, which included only 12 of the IGAP meta-analysis variants and the top 10 variants from 
AlzGene, whereas our Overall PRS and that of Sleegers, et al. included all of the IGAP variants. 
Given that our study is based on a preclinical sample of participants, the lack of associations with 
T-tau and P-tau is consistent with other findings suggesting that these are later markers of AD, 
whereas Aβ42 is an earlier marker[28]. 
The associations were stronger for Aβ deposition than for cognition, a finding that draw 
attention to the AD pathological cascade, which suggests that Aβ biomarkers become abnormal 
long before cognition during the development of AD[1]. Although our cohort may not be old 
enough to be experiencing detectable cognitive decline, we are able to detect differences in Aβ 
deposition using the pathway specific PRSs. The current diagnostic criteria for AD primarily 
concerns impairments in cognition, however, mounting evidence suggests that measurement of 
Aβ deposition could be used to diagnose AD at a much earlier stage than cognitive function is 
able to[28-30]. Since measuring Aβ deposition can be expensive and require access to a PET 
facility (amyloid PET) and experience in performing lumbar puncture that also is regarded as an 
invasive procedure (CSF Aβ), and proxy measures of Aβ based on peripheral blood proteins are 
not quite able to definitively identify abnormal Aβ levels[31], a pathway specific PRS, such as 
the one developed here, could be used to determine who has a higher genetic risk of having 
elevated Aβ deposits and thus should receive screening for Aβ accumulation. The ability to 
identify these individuals will be of particular importance if effective treatments for AD become 
available. 
Due to the limited sample size of participants with CSF and PiB data, it is possible that 
this study did not have sufficient power to detect some associations, particularly in our stratified 
analyses. It will be important to replicate associations with Aβ deposition using a larger sample 
size in order to validate our findings regarding pathway specific PRSs. The accuracy of our 
results is, in part, limited by current knowledge regarding the biological function of genes, which 
guided the development of the pathway specific PRSs used in this study. It is likely that in the 
future, we may learn that additional variants contribute to cholesterol metabolism and Aβ 
clearance. As our knowledge base improves, other important biological pathways involved with 
the development of AD should be investigated, such as Aβ production, tau pathology, and 
immune system response. Public repositories, such as Gene Ontology[32], could be useful tools 
to facilitate the creation of pathway specific PRSs.  
Pathway specific PRSs may be more predictive of disease-related traits or biomarkers 
than PRSs including all known disease variants. In particular, the Cholesterol Metabolism and 
Aβ Clearance PRSs appear to be more strongly associated with cognition and Aβ deposition than 
an Overall PRS and APOE alone. These PRSs could be useful in facilitating preventative, 
diagnostic, and treatment decisions, especially as more knowledge is gained on the genetic 
variants involved in specific biological pathways of AD and as therapies to target particular 
pathways become available. 
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